Recent Blog Articles

Managing irritable bowel syndrome without special drugs

Updated: June 01, 2007

Another IBS drug has been taken off the market because of serious side effects. Now what?

In March 2007, at the request of the FDA, the pharmaceutical company Novartis agreed to halt the sale of Zelnorm (tegaserod maleate), a drug used in the short-term treatment of irritable bowel syndrome (IBS) when the main symptom is constipation. Zelnorm was approved in 2002 for women with IBS and, later, for men and women under age 65 with chronic constipation. The FDA's request was based on an analysis showing that, compared with a placebo, Zelnorm slightly increased the risk for heart attack, angina, and stroke. But this wasn't the first sign of trouble for the drug. Its label had already been changed, in 2004, to include warnings about serious side effects, including ischemic colitis (lack of blood flow to the intestine).

To continue reading this article, you must log in.

Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.

  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »

I'd like to receive access to Harvard Health Online for only $4.99 a month.

Sign Me Up

Already a member? Login ».


As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.